SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 6.08% Passive Stake in STAAR Surgical Co.
Beneficial Ownership Disclosure (Schedule 13G)
Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a passive beneficial ownership of 6.08% in STAAR Surgical Co., totaling 3,000,000 common shares.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed a Schedule 13G indicating beneficial ownership in STAAR Surgical Co.
- The Reporting Persons beneficially own an aggregate of 3,000,000 common shares of STAAR Surgical Co.
- This ownership represents 6.08% of the total class of common shares outstanding.
- The percentage is based on 49,325,372 shares outstanding as of February 18, 2025, as reported in STAAR Surgical Co.'s Form 10-K filed on February 21, 2025.
- Armistice Capital, LLC, as the investment manager, exercises shared voting and dispositive power over these securities.
- Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own these shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 7
Explanation: The disclosure of a significant passive stake by a reputable investment firm is generally viewed positively by the market, signaling institutional confidence in the company.
Positives
- A significant institutional investor, Armistice Capital, LLC, has taken a substantial stake in STAAR Surgical Co., which can be viewed as a vote of confidence in the company's prospects.
- The investment is declared as passive, indicating that the firm is not seeking to influence or change the control of STAAR Surgical Co., which may suggest stability for current management and strategy.
Risks
- The document does not detail specific risks related to STAAR Surgical Co.'s operations or financial performance, as it is a beneficial ownership disclosure.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding STAAR Surgical Co.'s future performance or outlook.
Industry Context
This filing indicates a significant institutional investment in STAAR Surgical Co., a company operating in the medical devices sector, specifically known for its implantable lenses. Such investments reflect investor interest in the healthcare technology space.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional investor may be perceived positively, potentially boosting investor confidence and share price.
- Management: The passive nature of the investment suggests no immediate intent to influence corporate control, allowing management to continue executing its strategy without activist pressure from this specific investor.
Key Dates
| Date | Description |
|---|---|
| 2025-02-18 | Date as of which 49,325,372 shares of STAAR Surgical Co. common stock were reported outstanding. |
| 2025-02-21 | Date STAAR Surgical Co. filed its Form 10-K with the SEC, reporting the shares outstanding. |
| 2025-03-31 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-05-15 | Date the Schedule 13G statement was signed and filed by Armistice Capital, LLC and Steven Boyd. |
Keywords
STAAR Surgical Co., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Stake, SEC Filing, Healthcare, Medical Devices
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.